标题
Interleukin-23: A key cytokine in inflammatory diseases
作者
关键词
-
出版物
ANNALS OF MEDICINE
Volume 43, Issue 7, Pages 503-511
出版商
Informa UK Limited
发表日期
2011-05-17
DOI
10.3109/07853890.2011.577093
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis
- (2014) Yasunori Kageyama et al. Modern Rheumatology
- Elevated Serum Level of IL-23 Correlates with Expression of VEGF in Human Colorectal Carcinoma
- (2010) Biljana Ljujic et al. ARCHIVES OF MEDICAL RESEARCH
- B Cell-Targeted Therapies for Systemic Lupus Erythematosus
- (2010) R. John Looney DRUGS
- γδ T Cells Enhance Autoimmunity by Restraining Regulatory T Cell Responses via an Interleukin-23-Dependent Mechanism
- (2010) Franziska Petermann et al. IMMUNITY
- Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis
- (2010) Benoit Le Goff et al. JOINT BONE SPINE
- Triptolide Inhibits IL-12/IL-23 Expression in APCs via CCAAT/Enhancer-Binding Protein
- (2010) Y. Zhang et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: IL-23 Receptor Deficiency Prevents the Development of Lupus Nephritis in C57BL/6-lpr/lpr Mice
- (2010) V. C. Kyttaris et al. JOURNAL OF IMMUNOLOGY
- Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology
- (2010) Sofia Buonocore et al. NATURE
- Generation of pathogenic TH17 cells in the absence of TGF-β signalling
- (2010) Kamran Ghoreschi et al. NATURE
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-p40 Antibodies Ustekinumab and Briakinumab: Blockade of Interleukin-12 and Interleukin-23 in the Treatment of Psoriasis
- (2010) Mona Gandhi et al. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
- Infection, inflammation, and chronic diseases: consequences of a modern lifestyle
- (2010) Stefan Ehlers et al. TRENDS IN IMMUNOLOGY
- Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases
- (2009) Michael Elliott et al. Annals of the New York Academy of Sciences
- Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis
- (2009) L. Melis et al. ANNALS OF THE RHEUMATIC DISEASES
- Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis
- (2009) Yoshinaga Ito et al. ARTHRITIS AND RHEUMATISM
- Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis
- (2009) Gaby Palmer et al. ARTHRITIS AND RHEUMATISM
- HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats
- (2009) Monica L. DeLay et al. ARTHRITIS AND RHEUMATISM
- Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis
- (2009) Francesco Ciccia et al. ARTHRITIS AND RHEUMATISM
- The Association Between Interleukin-23 Receptor Gene Polymorphisms and Systemic Lupus Erythematosus
- (2009) Yi Li et al. DNA AND CELL BIOLOGY
- Briakinumab
- (2009) Xinaida Taligare Lima et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
- (2009) Erin E Longbrake et al. Expert Review of Neurotherapeutics
- Toll-like Receptor 7 Mitigates Lethal West Nile Encephalitis via Interleukin 23-Dependent Immune Cell Infiltration and Homing
- (2009) Terrence Town et al. IMMUNITY
- Interleukin-1 and IL-23 Induce Innate IL-17 Production from γδ T Cells, Amplifying Th17 Responses and Autoimmunity
- (2009) Caroline E. Sutton et al. IMMUNITY
- Interleukin-35: odd one out or part of the family?
- (2009) Lauren W. Collison et al. IMMUNOLOGICAL REVIEWS
- Reconciling id, ego, and superego within interleukin-23
- (2009) Cristina M. Tato et al. IMMUNOLOGICAL REVIEWS
- Interleukin-23 receptor gene variants in Hungarian systemic lupus erythematosus patients
- (2009) Eniko Safrany et al. INFLAMMATION RESEARCH
- CCR6 is required for IL-23–induced psoriasis-like inflammation in mice
- (2009) Michael N. Hedrick et al. JOURNAL OF CLINICAL INVESTIGATION
- T-bet is essential for encephalitogenicity of both Th1 and Th17 cells
- (2009) Yuhong Yang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
- (2009) Alice Gottlieb et al. LANCET
- Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis
- (2009) P. Hillyer et al. RHEUMATOLOGY
- No association between interleukin 23 receptor gene polymorphisms and systemic lupus erythematosus
- (2009) Hee-Sun Kim et al. RHEUMATOLOGY INTERNATIONAL
- Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORγt in γδ T cells
- (2009) Ferry Cornelissen et al. ARTHRITIS RESEARCH & THERAPY
- The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis
- (2008) B Rueda et al. ANNALS OF THE RHEUMATIC DISEASES
- Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis
- (2008) J E Hollis-Moffatt et al. ANNALS OF THE RHEUMATIC DISEASES
- Cytokines: From Gut Inflammation to Colorectal Cancer
- (2008) Massimo Fantini et al. CURRENT DRUG TARGETS
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
- (2008) Benjamin M Segal et al. LANCET NEUROLOGY
- The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt
- (2008) Nicolas Manel et al. NATURE IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started